IgAN治疗研究进展  

Research Progress in the Treatment of IgA Nephropathy

作　　者：李正子 马特安[1] 

机构地区：[1]长江大学附属第一人民医院肾内科,湖北 荆州

出　　处：《临床医学进展》2023年第7期11080-11087,共8页Advances in Clinical Medicine

摘　　要：IgA肾病(IgAN)是肾脏病中最为常见的一种类型,随着对IgA肾病认识的进一步加深,发现其目前无法治愈,发展到后期需要肾脏血液净化治疗,目前治疗目标以减少蛋白尿、控制血压、延长进展至末期时间为主。IgA肾病目前主要治疗方法包括RAS抑制剂的使用,糖皮质激素联合免疫抑制剂等,近些年随着IgA肾病发病机制研究加深,出现了许多新型治疗方案,本文就IgA肾病主流治疗及其进展进行综述。IgA nephropathy (IgAN) is one of the most common types of kidney disease. With the further deep-ening of the understanding of IgA nephropathy, it is found that it cannot be cured at present, and it needs renal blood purification treatment in the later stage. At present, the treatment objectives are mainly to reduce proteinuria, control blood pressure and prolong the time of progression to the end stage. At present, the main treatment methods of IgA nephropathy include the use of RAS inhibitors, glucocorticoid combined with immunosuppressants, etc. In recent years, with the deepening of the pathogenesis of IgA nephropathy research, many new treatment schemes have appeared. This pa-per reviews the mainstream treatment of IgA nephropathy and its progress.

关 键 词：IGA肾病 RAS抑制剂 糖皮质激素 免疫抑制剂 靶向治疗 免疫系统 SGLT2 扁桃体切除 

分 类 号：R69[医药卫生—泌尿科学]